Condition: Hepatocellular Carcinoma · BCLC Stage B Hepatocellular Carcinoma · BCLC Stage C Hepatocellular Carcinoma · Sponsor: University Hospital, Montpellier
The goal of this prospective clinical trial is to identify a predictive biomarker in patients with advanced HCC (stage B and C) using a combinatorial approach of the liquid biopsy. The main questions it aims to answer are: * Is multi-omic liquid biopsy approach able to identify a strong predictive biomarker of immunotherapy efficiency? * Is there a correlation between tissue biopsy (PD-L1 tissue level of expression) and liquid biopsy (detection of CTC expressing PD-L1) in HCC patients? Participants blood will be collected at several time points.
This description comes directly from the study's public registry record.
Thomas Bardol, M.D. · +33682882757 · t-bardol@chu-montpellier.fr
Catherine Guillemare · +33467332304 · c-guillemare@chu-montpellier.fr
Always discuss trial participation with your own doctor first.
| CHU Montpellier | Montpellier, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05810402